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The p53 DNA-binding domain harbors a conformationally
flexible multiprotein binding site that regulates p53 ubiquitina-
tion. A novel phosphorylation site exists within this region at
Ser269, whose phosphomimetic mutation inactivates p53. The
phosphomimetic p53 (S269D) exhibits characteristics ofmutant
p53: stable binding to Hsp70 in vivo, elevated ubiquitination in
vivo, inactivity in DNA binding and transcription, increased
thermoinstability using thermal shift assays, and max of
intrinsic tryptophan fluorescence at 403 nm rather than 346
nm, characteristic of wild type p53. These data indicate that
p53 conformational stability is regulated by a phosphoaccep-
tor site within an exposed flexible surface loop and that this
can be destabilized by phosphorylation. To test whether
other motifs within p53 have similarly evolved, we analyzed
the effect of Ser215 mutation on p53 function because Ser215
is another inactivating phosphorylation site in the conforma-
tionally flexible PAb240 epitope. The p53S215D protein is inac-
tive like p53S269D, whereas p53S215A is as active as p53S269A.
However, the double mutant p53S215A/S269A was transcription-
ally inactive andmore thermally unstable than either individual
Ser-Ala loop mutant. Molecular dynamics simulations suggest
that (i) solvation of phospho-Ser215 and phospho-Ser269 by pos-
itive charged residues or solvent water leads to local unfolding,
which is accompanied by local destabilization of the N-terminal
loop and global destabilization of p53, and (ii) the double ala-
nine 215/269 mutation disrupts hydrogen bonding normally
stabilizedbyboth Ser215 andSer269. These data indicate that p53
has evolved two serine phosphoacceptor residueswithin confor-
mationally flexible epitopes that normally stabilize the p53
DNA-binding domain but whose phosphorylation induces a
mutant conformation to wild type p53.
p53 protein is a sequence-specific DNA-binding protein and
transcription factor that can regulate the cellular response to
cellular stresses. Activating signals include virus infection, irra-
diation, hypoxia, and metabolic stress (1). The molecular basis
for p53 activation involves coordinated inhibition of the ubiq-
uitin-proteasome degradation system that is regulated by the
E3 ubiquitin ligase MDM2 and induction of sets of activating
enzymes including protein kinases, proline isomerases, and
acetyltransferases that regulate p53 responsive gene expres-
sion. Of these signaling pathways that activate p53 that include
enzymes like ATM, PIN, and p300, the most well characterized
signals are those mediated by phosphorylation.
The most highly conserved phosphorylation sites of human
p53 occur in the N-terminal transactivation domain at
Ser15/18/20 and the C-terminal CK2 phosphorylation site at
Ser392 (1). Phosphomimetic mutation of these sites can stimu-
late p53-dependent transcription (2), and mouse transgenes
with alanine-substituted mutations have increased cancer inci-
dence in stress or tissue-specific manner (3–5). The biochemi-
cal basis for these effects has been reported; transactivation
domain phosphorylation at Thr18 can directly inhibit MDM2
binding (6, 7), whereas Ser20 phosphorylation can stabilize p300
binding (8, 9). Ser392 phosphorylation can stimulate p53
sequence-specific DNA binding according to the ensemble
model of allostery (10) in part by stabilizing p53 tetramers from
the dimeric state (11). Phosphomimetic mutation of codon 392
increases the thermostability of the coreDNA-binding domain,
demonstrating an allosteric effect to the activation (12). There
are other phosphorylation sites on p53 that stimulate its func-
tion as defined using transgenics; one such site includes the
MAPKkinase site at Ser46 (13), but themolecular basis for these
activating effects on p53 structure and function is not as well
defined as is the former cluster of phosphoacceptor sites.
Post-translational modifications can also catalyze the inhibi-
tion of p53 protein; the most well characterized are those
induced by ubiquitination-degradation pathways, but there are
also kinase-signaling pathways that can inhibit p53. MDM2-
mediated degradation of p53 is the best characterized of the
p53-inhibiting pathways (14) that can in turn be stimulated by
MDM2 interactions with other proteins, including TAFII250
(15) andMDMX (16). Although there aremany phosphoaccep-
tor sites on MDM2 that have been identified, the best charac-
terized site with potential to stimulate MDM2-mediated inhi-
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bition of p53 is in the N-terminal MDM2 pseudosubstrate
motif, or “lid” (17, 18). In addition to the MDM2-stimulated
degradation pathway, there are three distinct kinase pathways
that directly target p53 and inhibit the protein function,
although the molecular basis for this inhibition is not known.
One inactivating phosphorylation site on p53 is at Ser315.
Although Ser315 phosphorylation can stimulate the specific
DNA-binding function of p53 (19) and DNA damage can acti-
vate p53 function via Ser315 phosphorylation in cells (20), this
phosphorylation in dividing cells is catalyzed by aGSK3-signal-
ing pathway that can promote the nuclear export and inhibition
of p53 under conditions of endoplasmic reticulum stress (21).
These data indicate that phosphorylation at Ser315 can inhibit
or activate p53 and therefore depends upon the context. A sec-
ond p53 inactivating kinase pathway is at Ser215, whose phos-
phorylation can be catalyzed by anAurora-dependent signaling
pathway (22), but the molecular basis for how this inhibits p53
is not known. The final kinase-inactivating pathway is triggered
by COP9, which phosphorylates p53 at Thr155, and this triggers
p53 degradation (23). As with the other inactivating site
reviewed above, the protein-protein interactions that are
driven by Thr155 phosphorylation are not defined.
In an accompanying paper (24), we report the identification
of a novel p53 phosphorylation site in a multiprotein docking
site in the DNA-binding domain of p53 at Ser269. This phos-
phorylation site is notable in that it occurs within the MDM2-
binding site (e.g. “ubiquitination signal”) that triggers p53 ubiq-
uitination and that it also forms docking sites for distinct class
of protein kinases (25). Phosphomimetic mutation at Ser269
suggested that this phosphorylation would inactivate rather
than activate p53 function in vivo. In this paper, we report on
the biochemical basis for p53 inactivation by Ser269 phosphor-
ylation. Using phosphomimetic mutants, we propose that
Ser269 phosphorylation inactivates p53 by direct destabilization
of the p53 core DNA-binding domain, thus inducing a mutant
conformation to wild type p53. Molecular dynamics simula-
tions further suggest specific mechanisms to explain how the
phosphate at Ser269 could destabilize p53 protein folding by
altering the allosteric effects of Gln100 and Thr102 on p53 con-
formational stability. These data indicate that p53 has evolved a
kinase pathway(s) that can regulate the conversion of WT p53
between folded and unfolded conformational ensembles and
suggest the existence of signaling cascades that can induce a
mutant conformation to the wild type p53 tetramer.
MATERIALS ANDMETHODS
Reagents and Plasmids—N-terminally tagged biotinylated
peptides were obtained from Mimotopes (Carlton, Australia).
Anti-p53 antibodies were DO-1, DO-12, PAb240, PAb1620,
CM-1, Ab-1 (anti-p21, Cell Signaling), 2A10 (anti-Mdm2),
Hsp70, andHsp90 (Cell Signaling). pcDNA3.1 p53 and pCMV-
Mdm2 plasmids were described (26); pRSET p53 core domain
expression plasmid was obtained from Dr. P. Nikolova (27).
Single amino acid mutations were introduced into wild type
p53 at Ser269 according to the QuikChange site-directed
mutagenesis kit (Stratagene) using pcDNA 3.1 p53, pExpr p53,
and pRSETp53DNAcore domain as templates, and the follow-
ing oligonucleotides were used for mutagenesis (underlined):
p53 S215A, 5-c act ttt cga cat gct gtg gtg gtg ccc-3 (forward
primer) and 5 ggg cac cac cac agc atg tcg aaa agt g 3 (reverse
phase); p53 S215D, 5-c act ttt cga cat gat gtg gtg gtg ccc-3
(forward primer) and 5-ggg cac cac cac atc atg tcg aaa agt g
(reverse primer); p53 S269A, 5-g gga cgg aac gcc ttt gag gtg
cg-3 (forward primer) and 5-cg cac ctc aaa ggc gtt ccg tcc c-3
(reverse primer); p53 S269D, 5-ctg gga cgg aac gac ttt gag gtg
cg-3 (forward primer) and 5-cg cac ctc aaa gtc gtt ccg tcc
cag-3 (reverse primer).
Peptide ELISA—Biotinylated unphosphorylated and phos-
phorylated peptides were captured onto ELISA wells coated
with streptavidin and blocked with 3% BSA in PBS-Tween as
described previously to measure Mdm2 binding (17) or mAb
binding (6).
Cell Culture, Transfection, and Analysis—H1299 cells were
cultured in RPMI 1640 medium supplemented with 10% fetal
bovine serum. Cells were harvested and lysed using urea lysis
buffer as described previously (28) unless otherwise stated. For
mutant p53 conformation analyses, p53 within these lysates
was analyzed by ELISA using PAb1620 and DO-1 as described
previously (29) or by immunoprecipitation. For immunopre-
cipitation, cell lysates (100 ng) were precleared with protein G
beads (Sigma) for 1 h before incubation with 1 g of DO-1,
PAb1620, or PAb240 at 4 °C.
DNA Binding Assays—BL21 AI Escherichia coli were trans-
formed with pRSET p53 core wild type or S269A or S269D
mutant form of the p53 core domain (residues 94–312) and
were expressed and purified from soluble lysates using SP cat-
ion exchange and heparin affinity Hi-Trap columns (Amer-
sham Biosciences), as described previously (27, 30). The DNA
binding activity of p53 was examined by EMSA. p21 promoter-
derived sequences (31) were labeled with [-32P]ATP and incu-
bated with purified recombinant wild type or serine 269
mutants of p53 core domain in 30 mM Hepes pH 7.5, 50 mM
KCl, 5% glycerol, 0.4mMDTT, 0.1mg/ml BSA, and 0.5%Triton
X-100 containing 1g of poly(dI-dC) DNA (Sigma) and 500 ng
of salmon sperm DNA in a final volume of 12 l for 30 min at
room temperature. Reactions were processed by adding 6
DNAsample buffer, loaded onto 5%polyacrylamideTris borate
gels, and separated by electrophoresis at 35 mA for 3 h at 4 °C.
Gels were dried, and images were analyzed following exposure
to a phosphor storage screen.
Intrinsic Fluorescence—Fluorescence emission spectra of the
purified wild type, S269A, and S269D forms of the p53 core
domain were measured using a SPEX FLUOROMAX-3 spec-
trofluorometer as described previously (32). Excitation wave-
lengths of 280 and 295 nm were used for tyrosine and trypto-
phan residues, respectively, and tyrosine and tryptophan
fluorescence spectra were recorded from 300 to 350 nm and
from 320 to 450 nm, respectively, at 10 °C using 0.5-nm steps
and an integration time of 1 s. The final spectrumwas the aver-
age of three emission scans minus the background buffer (50
mM Tris, pH 7.2, 5 mM DTT) fluorescence scan alone.
Thermal Protein Unfolding Assay—p53 protein unfolding
was monitored using fluorescent SYPRO Orange dye (Invitro-
gen). Recombinant p53 core proteins were diluted to a final
concentration of 2.5M in buffer (50mMTris, pH 7.2, and 2mM
DTT) in the presence or absence of increasing concentrations
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of ligand (0.1–30 mM MgCl2 or 1–8 M annealed consensus
DNA (27)) and incubated on ice for 15 min before SYPRO
Orange was added to a final concentration of 5 (from a stock
of 5000). Sampleswere aliquoted into a 96-well PCRplate and
sealed with optical quality sealing film (Bio-Rad). Thermal pro-
tein unfolding was carried out using an iCycler iQ real-time
PCR system (Bio-Rad) by heating samples from 15 to 55 °C in
0.5 °C increments with a 30-s incubation at each increment.
The fluorescent intensity was measured using excitation/emis-
sion wavelengths of 485/575 nm in relative fluorescent units
(RFU), and the thermal denaturation graphs were plotted as a
function of the gradient of protein unfolding against the tem-
perature gradient (d(RFU)/dT).
MolecularDynamicsMethods—For themodeling studies, we
used chain A from the crystal structure of the p53 core domain
dimer bound to DNA (Protein Data Bank entry 2AHI resolved
at 1.85 Å) (33). This chain was chosen because it had the least
number of disordered residues. Modeling studies were carried
out using the AMBER9 (34) package. The missing atoms were
built using standard geometries as implemented in AMBER.
Mutants were constructed in silico using SCWRL (35). The
parameters for phosphoserine were taken from the AMBER
parameter data base at University of Manchester (available on
the World Wide Web).
TheDNA-binding domain of p53 consists of a zinc ion that is
coordinated to three Cys residues and one His residue, and the
parameters for this coordination were taken from earlier stud-
ies (36, 37). Each system was solvated with a box of TIP3P (38)
water molecules such that the boundary of the box was at least
10 Å from any protein atom. The positive charges in the system
were balanced by adding chloride ions. The Parm99 force field
was used for intermolecular interactions. The particle mesh
Ewaldmethod (39) was used for treating the long range electro-
statics. All bonds involving hydrogen were constrained by
SHAKE (40). A time step of 2 fs was used for propagating the
dynamics. Each system was initially minimized for 2000 steps
using steepest descent and conjugate gradient minimizers to
remove any unfavorable interactions between the protein and
the solvent. This was followed by heating each system to 300 K
over 75 ps under normal pressure/temperature conditions.
Subsequently, each system was simulated for 40–48 ns at
constant temperature (300K) and pressure (1 atm) (41), and the
structures were stored every 2 ps for analysis. Analysis was car-
ried out using VMD (42), and figures were made using PyMOL
(43).
RESULTS
The Phosphomimetic p53S269D Is in an Unfolded or Mutant
Conformation—A variety of mechanisms could account for
inactivation of p53 following phosphorylation at Ser269 (24).
Inactivating p53 mutation of one neighboring residue within
this MDM2-binding site in the S9-S10 linker region (p53F270A)
has been shown to unfold p53 protein and promote “hyperu-
biquitination” of p53 in vivo (44). This is attributed to enhanced
MDM2 binding affinity to destabilized, unfolded p53 mutants
(like p53R175H) due to exposure of the second MDM2 binding
site in theDNA-binding domain of p53 (29, 45). Indeed,MDM2
protein preferentially binds to peptides derived from this con-
formationally sensitive region of p53 (Fig. 1A, peptide 17), and
phosphorylation of p53 at Ser269 does not inhibit MDM2 inter-
actions with this motif (Fig. 1B).
We examined therefore whether p53S269D is phenotypically
equivalent to mutant, inactive, and unfolded p53 as defined by
sensitivity to ubiquitin-like modification in cells. Immunoblot-
ting lysates fromH1299 cells transfectedwithwild type p53 and
with p53S269A and p53S269D mutants reveals a ladder of higher
molecular mass bands in lysates from cells expressing p53S269A
and p53S269D mutants (Fig. 1C, lanes 7 and 8 versus lane 6), a
phenomenon indicative of p53 ubiquitin-like modifications
(29). The intensity of the high molecular mass p53 ladder of
“ubiquitin-like adducts” was significantly increased when pro-
tein degradation was inhibited by treating H1299 cells with the
proteasome inhibitor, MG-132 (Fig. 1C, compare lanes 1–4
with lanes 5–8). Thus, p53S269D is phenotypically equivalent to
p53R175H in that it is inactive (24) and highly sensitive to ubiq-
uitin-like adducts in cells. By contrast, because transfected
p53S269A can be more active thanWT p53 at inducing elevated
levels of MDM2 protein (24), the observed ubiquitin-like
adducts of p53S269A can be attributed to enhanced induction
of endogenous MDM2 protein. This phenomenon has been
observed previously using the gain-of-function wild type p53
mutants in the S9-S10 loop: p53S261A and p53S264A (44) (high-
lighted in Fig. 2) (24).
We next evaluated whether the phosphomimetic p53S269D
protein exhibits amutant conformation in vivo, thus explaining
the inability of p53S269D to act as a transcription factor (24). To
test this, we used conformation-specificmonoclonal antibodies
to examine folding of the p53 isoforms. p53 alleles were trans-
fected into H1299 cells, and the proteins were immunoprecipi-
tated from lysates using PAb1620 and PAb240 monoclonal
antibodies, which specifically recognize folded/wild type and
denatured/mutant conformations of p53, respectively (46). The
DO-1, PAb1620, and PAb240 antibodies immunoprecipitated
equivalent levels of transfected wild type p53 (Fig. 2A, lanes
4–6, respectively). The equivalent amounts of PAb1620
(native/folded) and PAb240 (mutant/unfolded) reactive wild
type p53 are due to the equilibrium that exists between the
“folded” and “unfolded” states of p53 protein (47). Transfection
of p53S269A into cells also produced p53 protein in an equiva-
lent folded and unfolded equilibrium (Fig. 2A, lanes 7–9).
However, the amount of p53S269D immunoprecipitated using
PAb1620was significantly lower than that of wild type p53 (Fig.
2A, compare lane 12 with lanes 6 and 9). This was not due to
lowered expression of the p53S269D mutant because blotting of
the total cellular p53 pool shows equivalent expression of p53
wild type, p53S269A, and p53S269D forms (Fig. 2B). The ratio of
folded to non-folded p53S269Dmutant was further examined by
quantitative ELISA. Lysates from cells transfected with wild
type and p53S269A showed significant and comparable binding
to PAb1620 (Fig. 2, C versus D). In contrast, p53S269D showed
significantly less binding to PAb1620 compared with wild type
p53 (Fig. 2, C versus D), confirming that the phosphomimetic
mutant is in a non-native conformation.
Codon 269 is adjacent to Phe270 and Asn268, andmutation of
either residue to Ala270 or Asp268 can either destabilize or sta-
bilize the p53 tetramer, respectively (29, 44, 48). For example,
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the N268D mutation can form an altered hydrogen bond net-
work that links the S1 and S10 sheets of the -sandwich in a
more energetically stable manner. It is therefore possible that
the S269Dmutation destabilizes the p53 core domain in aman-
ner similar to the F270A mutation (29). To determine whether
loss of transcriptional activity of p53S269D was due to reduced
DNA binding, we examined the ability of the p53 core domain
variants to bind DNA in a sequence-specific manner at 4 °C.
Recombinant wild type p53, p53S269A, and p53S269D core
domain mutants were expressed and purified from E. coli. The
wild type p53 and p53S269A core domain proteins both demon-
strated a concentration-dependent increase in binding to the
p21 promoter sequence (Fig. 3). By contrast, p53S269D did not
bind to the p21 promoter element (Fig. 3), demonstrating that
phosphomimetic mutation of p53 at serine 269 ablates its
sequence-specific DNA binding function.
In order to further evaluate whether the phosphomimetic
mutant is in a misfolded conformation in cells, we analyzed
whether this p53 mutant can interact with Hsp70. This molec-
ular chaperone interacts with unfolded mutant forms of p53
and can target the mutant protein for degradation (49). Analy-
sis of immunoprecipitated p53 shows that Hsp70 associates
with the p53S269Dmutant (Fig. 4A, lane 4 versus lane 1) yet does
not co-immunoprecipitate with wild type p53, supporting the
hypothesis that mutation of serine 269 to aspartate leads to p53
unfolding. Surprisingly, p53S269A was also found to co-immu-
noprecipitate Hsp70, despite its wild type-like activity (24).
This suggests that this mutant (S269A) is partially destabilized,
despite being fully active. In fact, biophysical studies (see below)
confirm and indicate that p53 protein instability in vitro can be
uncoupled from loss-of-function effects.
Together, these findings indicate that mutation of serine 269
to the phosphomimetic aspartate form leads to p53 protein
unfolding in vivo and suggests that phosphorylation of p53 pro-
tein at serine 269 may induce conformational changes within
p53 that cause it to adopt a mutant conformation. This may
account for the observed loss of DNA binding in vitro and
lowered transcriptional activity toward endogenous p21 and
FIGURE1.Mutationofp53at codon269 increasesp53ubiquitination.A,mapping the regionof p53DNA-bindingdomainboundbyMDM2.MDM2binding
to p53 peptides was determined by ELISA. Streptavidin-coated plates were coated with biotinylated peptides and incubated with MDM2, and the amount of
MDM2 captured was determined using monoclonal 2A10 followed by chemiluminescence. The data are plotted as MDM2 binding (relative light units) as a
function of MDM2 levels. B, effects of serine 269 phosphorylation onMDM2 binding to its p53-DNA-binding domain docking site. MDM2 binding to wild type
and Ser269-phosphorylated p53 BOX-V domain peptide (LGRNSFEVR) was examined by ELISA as in A. C, mutation of p53 at codon 269 increases p53 ubiquiti-
nation. pcDNAexpression vectors encodingp53, p53S269A, or p53S269Dwere transfected intoH1299 cells (without orwith 10MMG-132 treatment for 4 hprior
to harvesting). Lysates (10 g) were immunoblotted with DO-1 to detect total p53 and total ubiquitin-like modification of p53. Arrow indicates p53. R.L.U.,
relative light units. Error bars, S.D.
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Mdm2 promoters. Biophysical analyses were thus initiated to
determine whether the phosphomimetic p53S269D was in fact
misfolded because these methodologies could reflect funda-
mental thermodynamic properties of the wild type and mutant
p53 core DNA-binding domains.
Aspartate Mutation of Codon 269 Produces a Mutant p53
Conformation; Implications for Control of p53 Folding by Phos-
phorylation at Serine 269—Intrinsic tyrosine or tryptophan
fluorescence is highly sensitive to its local environment, and
changes in fluorescence can reflect conformational changes,
ligand binding, or denaturation. These properties have been
useful in defining the conformational flexibility and thermody-
namic instability of wild type p53 at physiological temperatures
and for defining the enhanced instability of tumor-derived
mutations in the p53 core domain (27, 30, 50). The structural
integrity of p53 wild type, p53S269A, and p53S269D mutants was
examined by studying the intrinsic fluorescent properties
within the purified core domain.
The p53 core domain contains a sin-
gle tryptophan residue (Trp146),
which is not freely accessible on the
surface and faces the interior of the
p53 protein (PyMOL, Protein Data
Bank entry 2FEJ, in solution). The
p53 core domain also contains eight
tyrosine residues, some of which are
accessible on the surface of the pro-
tein and some of which are buried in
the interior. Strong tyrosine fluores-
cence spectra were observed for the
wild type p53 and p53S269A core
domain proteins, peaking at 302 and
303 nm, respectively (Fig. 5A). The
intrinsic fluorescent properties of
the tryptophan residue within the
wild type p53 and p53S269A core
domains was also examined, and
both showed similar tryptophan
fluorescent spectra (Fig. 5B). The
spectra of p53S269A was, however,
shifted to a longer wavelength (red
shift) relative to the wild type core
domain with a max peak of trypto-
phan emission at 350 nm compared
with 346.5 nm (Fig. 5B). Previous
studies have shown that natively
folded p53 exhibits a tyrosine-dom-
inated fluorescent spectrum with a
maximum tyrosine emission at 305
nm (27, 50), suggesting that like p53
wild type, p53S269A exists in a native
conformation. The red shift in tryp-
tophan and tyrosine fluorescence
may, however, suggest that p53S269A
differs from that of p53 wild type
andpossibly exists in amore openor
flexible conformation.
By contrast, the tryptophan and
tyrosine fluorescent spectra obtained for the p53S269D core
domain mutant were very different from that of the p53 wild
type (Fig. 5,A andB).Wewere unable to detect distinct peaks of
tyrosine fluorescence characteristic of wild type p53 (Fig. 5A),
and the tyrosine spectrum obtained for p53S269D was only mar-
ginally above that of the background buffer. By contrast, a
strong peak of tryptophan fluorescence was detected; however,
the fluorescence spectra obtained did not exhibit the character-
istic peak (346 nm) observed in the presence of the wild type
p53 and instead displayed a significant red shift to longer wave-
lengths peaking with a max of 403.5 nm (Fig. 5B). Because the
fluorescent spectrum of p53 core domain changes from a tyro-
sine-dominated to a tryptophan-dominated spectrum upon
denaturation (27, 50), these findings indicate that p53S269D
exists in a denatured or aggregated form and suggest that phos-
phomimeticmutation of p53 at serine 269 leads to denaturation
of the core domain.
FIGURE2.Phosphomimetic substitutionat codon269 inducesamutant conformation top53.A–D, effects
of the S269Dmutation on p53 conformation.A and B, H1299 cells were transfectedwith eitherwild type or the
mutant p53 vectors. p53 forms were immunoprecipitated from lysates using monoclonal antibodies: (i) DO-1
(panspecific; lanes 1, 4, 7, and 10); (ii) PAb240 (detecting misfolded p53; lanes 2, 5, 8, and 11), or (iii) PAb1620
(detecting native p53; lanes 3, 6, 9, and 12). p53 in the immunoprecipitates was detected using CM-1 (panspe-
cific p53 rabbit IgG) (A), whereas total expression of p53 protein isoformswas determined by immunoblotting
lysates (B). The intensity of p53-reactive bands was quantified by Scion Image software, and the ratio of
PAb1620- to PAb240-reactive p53 is indicated below A. C andD, H1299 cells were transfectedwithwild type or
the indicated mutant p53 expression vectors, and p53 forms were captured on solid phase precoated with
PAb1620 (C) or DO-1 (D) by incubations with lysate as indicated. Captured p53 was quantified using chemilu-
minescence. The data are plotted as p53 bound to the respective monoclonal antibody as a function of lysate
concentration in relative light units (R.L.U.). Error bars, S.D.
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The DNA-binding domain of p53 is highly structured; how-
ever, the thermodynamic stability of this region is relatively
low, and mutations can reduce the thermodynamic stability of
p53 (51, 52). To examinewhether phosphomimeticmutation of
serine 269 alters the thermodynamic stability of p53, we mon-
itored the thermal unfolding transition of the p53 core domain
using SYPROOrange fluorescent dye, an environmentally sen-
sitive dye whose fluorescence is low in aqueous solutions yet
increases in a hydrophobic environment. This dye is a useful
tool tomonitor the transition in protein folding during thermal
denaturation because exposure of the hydrophobic interior of a
protein upon heating enhances the fluorescent intensity of the
dye (53, 54). SYPROOrange fluorescencewasmeasured at tem-
peratures ranging from 15 to 50 °C. The fluorescent emission in
the presence of p53 wild type and p53S269D began to increase
around32–34 °C and increased to a maximum around41–
44 °C (Fig. 6A). Thereafter, the fluorescent intensity decreased,
presumably due to aggregation of unfolded p53 protein-dye
complexes quenching emission. By plotting the gradient of fluo-
rescent emission against the temperature (Fig. 6B), the mid-
point temperature (Tm) of p53 core domain folding-unfolding
transition can be obtained. Wild type p53 core domain dis-
played an unfolding transition peakwithmidpoint temperature
of 40.5 °C (Fig. 6B), whereas p53S269A displayed a midpoint
transition peak at 37 °C (Fig. 6B), suggesting that wild type
and p53S269A core domains exist in two thermodynamically dis-
tinct states. Because the intrinsic fluorescence data suggests
p53S269A may exist in a more open conformation (Fig. 5, A and
B), the lowered thermodynamic stability of p53S269A may be
due to greater conformational flexibility within the p53S269A
protein.
Very little change in SYPRO Orange fluorescent emission
was observed in the presence of p53S269D (Fig. 6A), although a
small but noticeable shoulder was obtained when the gradient
of fluorescent emission in the presence of p53S269D was plotted
FIGURE 3. Phosphomimeticmutation of p53 at serine 269 ablates its spe-
cific DNA binding function. The DNA binding function of p53 containing
codon 269mutations wasmeasured using a radiolabeled p21DNA sequence
using native gel electrophoresis. The binding activity of p53 wild type,
p53S269A, or p53S269D (200, 300, and 400 ng) was determined in reactions
containing the p21 promoter sequence. DNA-p53 complexes were resolved
using a native polyacrylamide gel, dried, and detected by storage phosphor
screen. Bound and free probe are highlighted by arrows.
FIGURE 4. Hsp70 co-immunoprecipitates with p53-S269D. A, H1299
cells were transiently transfectedwith p53wild type, S269A, or S269D, and
total p53 was immunoprecipitated (IP) using DO-1. Co-immunoprecipitat-
ing Hsp70 was detected by immunoblotting (IB). Bottom panel, equal
immunoprecipitation of p53 from lysates was determined by blotting
with anti-rabbit p53 (CM-1). Total Hsp70 (B) and Hsp90 (C) levels in H1299
cells following transfection with p53 wild type, S269A, or S269D were
determined by immunoblotting.
FIGURE 5.Alanine or aspartate substitution of serine 269 generates con-
formational differences within the p53 core domain. Tyrosine (A) and
tryptophan (B) fluorescence spectra of the wild type p53, p53S269A, and
p53S269D core domain variants were determined and corrected for the pres-
ence of buffer background spectra as described previously (32). The fluores-
centmaxima for both tryptophan and tyrosine emission and the correspond-
ing wavelength are detailed in the table below. cps, counts per second.
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against temperature (Fig. 6B). This gave p53S269D a calculated
midpoint temperature of transition of 29.5 °C. This is signifi-
cantly lower thanTm calculated for wild type p53 and p53S269A,
suggesting that phosphomimetic mutation of serine 269 in-
creases the thermodynamic instability of the p53 core domain.
Little if any unfolding of p53S269D was observed at the temper-
atures required to unfold the wild type p53 and p53S269A
proteins, suggesting that only a small proportion of the purified
p53S269D core domain pool has a thermostability similar to that
of wild type p53. The intrinsic fluorescent data show that
p53S269D exists in an unfolded, aggregated form (Figs. 5A and
6B). This would account for the lack of SYPRO Orange bind-
ing because greater melting temperatures may be required to
unfold higher order aggregates.
To further examine the differences in thermodynamic stabil-
ity of p53 and p53S269A, we investigated the impact ligands
would have on thermal unfolding transitions. p53 consensus
DNA had a significant effect on the thermal stability of both
wild type p53 and p53S269A. The unfolding transition peak of
p53 wild type was increased to 43, 44.5, and 46.5 °C in the pres-
ence of 1, 3, and 8 M consensus DNA, respectively (Fig. 6C).
Because the consensus DNA did not display any change in fluo-
rescence above background at any of the temperatures tested
(data not shown), these data indicate that binding to consensus
DNA induces changes that significantly enhance the thermo-
dynamic stability of the p53 core domain.
Consensus DNA also altered the fluorescent profile of the
p53S269A mutant (Fig. 6D). The unfolding kinetics of p53S269A
was shifted in the presence of 1, 3, and 8 M consensus DNA,
and the unfolding transition midpoint temperatures were
increased from 37 to42.5 °C (Fig. 6D). These data show that,
like that ofwild type p53, the stability of p53S269A is significantly
enhanced upon binding to DNA. However, DNA binding does
not overcome the marginal thermal instability incurred by ala-
nine mutation of serine 269 because even in complex with
DNA, the p53S269A core domain remains slightly less thermo-
dynamically stable than the wild type p53 core domain com-
plexed to DNA (Tm of42.5 °C versus Tm of46.5 °C), and the
FIGURE 6. Thermal stability of p53 serine 269 substitution mutants. A, thermal melting profile of p53 mutants. Unfolding of p53 mutants was monitored
between 15 and 50 °C using SYPRO Orange fluorescent dye, and melt curves were generated by plotting SYPRO Orange fluorescence as a function of
temperature in relative fluorescent units (RFU). B, phase transitions in the thermal melting profile. The gradient of p53 unfolding was plotted as a function of
temperature to obtain themidpoint temperature transition (Tm) for each variant.C andD, effect of ligands onp53unfolding. Unfoldingof p53wild type (C) and
p53S269A (D) was measured between 15 and 60 °C in the presence of increasing concentrations of p21 consensus DNA. The midpoint unfolding transition
temperatures are indicated below. Thermal analyses were performed in triplicate; however, a single trace representative of each mutant is shown.
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p53S269A-DNA complex appears structurally distinct from
the wild type p53 core domain-DNA complex. As a control, the
addition of magnesium ions did not qualitatively alter the
unfolding kinetics of wild type p53 or p53S269A (data not
shown).
Two Conformationally Flexible Loops Containing Phospho-
acceptor Sites Regulate p53 Conformation and Activity—Char-
acterization of the codon 269 mutants has shown that the ala-
nine mutant can induce a more open conformation as defined
by intrinsic fluorescence and that this mutant does not reduce
the specific activity of p53 in cells. However, the Ala269 mutant
does increase thermoinstability in vitro and increases Hsp70
interactions in vivo. By contrast, the phosphomimetic mutant
p53S269D is highly destabilized, inactive, and characteristic of
unfolded mutant p53. These data suggest first that this confor-
mationally flexible loop in p53 has evolved a serine residue to
maintain a degree of intrinsic inflexibility (i.e. flexibility or
a more open conformation can be improved upon by alanine
mutation of codon 269). Second, the serine has evolved to func-
tion as a phosphoacceptor site whose phosphorylation drives
the unfolding and destabilization of wild type p53. This would
create a rapid and flexible mechanism to convert the wild type
p53 tetramer to a mutant conformation. Although the physio-
logical functions of this switch are not yet evident and will
require additional research, the existence of this phosphoryla-
tion site provides a novel mechanism to unfold and inactivate
wild type p53 in vivo.
In order to further evaluate the evolutionary significance of
this post-translational mode of p53 inactivation, we also exam-
ined a previously identified phosphorylation site of p53 at
Ser215. Phosphorylation at the Ser215 site of p53 was previously
shown to occur in cells, and phosphomimetic mutation at
Ser215 created a transcriptionally inactive p53 (22). The mech-
anism accounting for p53 inactivation following Ser215 phos-
phorylation has not been described. In analyzing this Ser215
phosphorylation site, we noticed that it occurs at another so-
called conformationally flexible epitope, bound by the mono-
clonal antibody PAb240 (55). This mAb was the original probe
used to demonstrate that mutant p53 protein is unfolded in
human cancer cells (56). We evaluated the alanine-substituted
mutants of codon 215 mutants to determine whether this flex-
ible motif behaved like the codon 269 mutants and secondarily
whether these two conformationally flexible motifs interact
allosterically and alter the folding of the p53 DNA-binding
domain. For example, we could predict that Ala215 mutation
could overcome the Asp269 mutation or vice versa. Alterna-
tively, because Ala269 andAla215 are individually fully active but
with enhanced conformational flexibility, it could be predicted
that the double mutant S215A/S269A would be more active
than WT p53. However, neither of these two outcomes was
observed (see below). The structural integrity of wild type p53,
p53S215A, p53S269A, and the double mutant p53S215A/269A was
tested to evaluate these possible outcomes.
Tyrosine fluorescence spectra observed for thewild type p53,
p53S215A, p53S269A, and the double mutant p53S215A/S269A core
domain proteins peaked from 300 to 301.5 nm (Fig. 7A),
indicating that all alanine-substituted mutants were similar in
their folding properties to wild type p53 and that the double
alanine-substituted mutant did not have characteristics of
unfolded mutant p53 (Fig. 5). However, the intrinsic trypto-
phan fluorescence within the p53S215A and the double mutant
p53S215A/S269A core domains also revealed differences similar
to those seen with the p53S269A mutant. The spectrum of
p53S215A was shifted to a longer wavelength (red shift) re-
lative to the wild type core domain although not to the
degree observed using p53S269A (Fig. 7B). The double mutant
p53S215A/S269A also exhibited a red shift in intrinsic tryptophan
fluorescence that is also indicative of a more open or flexible
conformation. There was no apparent synergy in red shift using
the double alanine-substituted p53 mutant. Together, these
studies suggest that, like p53S269A, p53S215A also exists in a
native and more “opened” conformation.
The stability of wild type p53, p53S215A, p53S269A, and the
double mutant p53S215A/S269A proteins was also examined in
thermal shift assays in order to compare the rate of p53S215A
unfoldingwith that of p53S269A. Relative towild type p53,which
exhibits a thermal transition at 41 °C, both Ala215 and Ala269
mutations showed an equivalent increase in the thermal insta-
bility of p53 by approximately the same temperature of 4 °C
(Fig. 8, A and B). However, the double mutant displayed a fur-
ther enhanced thermoinstability 7 °C below wild type p53
(Fig. 8). Together, these data indicate that each of these
conformationally flexible loops maintains p53 thermo-
stability to equivalent degrees, and removing both serine res-
idues precludes further the acquisition of a wild type confor-
mation. The thermal shift assays were also performed
in the presence of increasing DNA concentrations, where
enhanced thermostability of 4–5 °C was observed using
wild type p53, p53S215A, and p53S269A proteins (Fig. 9, A–C).
FIGURE 7. Alanine substitution of serine 215 also generates conforma-
tional differences within the p53 core domain. Tyrosine (A) and trypto-
phan (B) fluorescence spectra of the wild type p53, p53S215A, p53S269A, and
p53S215A/S269A core domain variants were determined and corrected for the
presence of buffer background spectra as described previously (32). The
fluorescent maxim for either tryptophan or tyrosine emission and the corre-
sponding wavelength are detailed in C. RFU, relative fluorescent units.
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The double mutant p53S215A/S269A exhibited an increased
thermal shift of 2.5 °C (Fig. 9D), indicating that the protein
can still interact with the DNA ligand (as seen in Fig. 9F) but
not to the extent of wild type p53 or the single alanine-sub-
stituted mutants (see Fig. 9E).
We finally evaluated the activity of the p53S215A, p53S269A,
and p53S215A/S269A and mixed alanine/aspartate mutants in
cells to determine whether single and double loop mutants
affected p53 function in vivo. As observed using the single
S269A or S269Dmutant p53s (Fig. 10, lanes 4 and 5), alanine
or aspartate mutations at codon 215 produced a p53 that is
either fully active or inactive, respectively (Fig. 10, D and E,
lane 2 versus lane 3). The double mutants provided addi-
tional evidence that p53 conformational integrity can be
controlled by the surface loop mutants. The double alanine
mutant (S215A/S269A), although in a wild type conforma-
tion as defined by (i) enhanced flexibility (Fig. 7), (ii) signif-
icant destabilization in thermal shift (Fig. 8), and (iii) ability
to be stabilized by DNA in vitro at 4 °C (Fig. 9), was com-
pletely inactive as a transcription factor as defined by loss of
p21 and MDM2 protein production (Fig. 10, lane 6). The
mixed aspartate/alanine mutant was also inactive (Fig. 10,
lanes 7–9). Together, these data suggest that p53 has evolved
two serine residues that maintain a degree of thermody-
namic stability but whose individual phosphorylation can
unfold and produce a p53 with a mutant-like conformation.
The negative dominance of the double alanine-substituted
mutant further suggests that at least one of the two serine
residues is required to maintain thermostability of p53.
The Effects of Phosphoserine on p53 Conformation Using
Molecular Dynamics Simulations—Molecular dynamics simu-
lations were carried out on the core domain of wild type p53
and its phosphorylated states (phosphorylated at Ser215 and
separately at Ser269).We also carried out simulations on S269D,
S269A, and S215A/S269A double mutants. In the wild type
state, molecular dynamics simulations show (Fig. 11A, ii) that
the side chain of Ser269 makes hydrogen bonds with Gln100 and
Thr102 and also with solvent water molecules (the crystal struc-
ture by itself does not show any hydrogen bonds between Ser
and the other two residues). The N-terminal loop is tethered to
the surface of the protein by a few hydrogen bonds, and these
are made largely with the S10 -strand. Upon phosphorylation
at Ser269, the highly negatively charged phosphate moiety
involves Gln100 and Thr102 in hydrogen bonds for20 ns (Fig.
11A, iii). However, with no cationic residues in the vicinity of
this phosphate to stabilize it through salt bridges, the nega-
tively charged phosphate is energetically more stable if well
solvated by water molecules. As this site fills with water, the
N-terminal loop moves away from it by up to 8 Å after 45 s
(Fig. 11A, iv). These events are also accompanied by desta-
bilization of the DNA binding regions and the dimerization
interface.
When Ser269 is mutated to alanine, the hydrogen bonds that
Ser269 made with Gln100 and Thr102 are replaced by transient
hydrogen bonds to solvent and to various surrounding atoms
(Fig. 11B, i). The side chain of Ala is stabilized by the hydropho-
bic side chains of Leu252 and Ile254 located on -strand S9.
Overall, this mutation does not appear to cause as much per-
turbation as the phosphorylation at Ser269. In contrast, the
S269D mutation initially maintains the hydrogen bond with
Gln100 and Thr102 for 40 ns, after which a major conforma-
tional change in the N-terminal loop occurs, which is accom-
panied by a flip of Lys101 (its terminal amine moves by11 Å).
This results in the formation of a salt bridge with the side chain
of Asp269 (the hydrogen bond with Gln100 is lost; Fig. 11B, ii).
This is also accompanied by the formation of a new hydrogen
bond between Asp269 and Gln130 that in turn perturbs the spa-
tially contiguous DNA binding region. Together, these data
highlight the importance of the interaction of the S10- strand
and the motif preceding the first -strand in the DNA-binding
domain of p53.
Ser215 is initially hydrogen-bonded to the backbone of
Leu206. Within 2 ns, Arg209, which is located on the loop con-
necting S6 and S7 and is exposed to solvent in the crystal struc-
ture, undergoes a local conformational change and moves11
Å and makes a salt bridge with Asp258 (located on S4), which is
also hydrogen-bonded to Arg158. In this process, Ser215 gets
buried (Fig. 11B, iv). Phosphorylation at Ser215 initially leads to
the formation of a salt bridge between the phosphate and
Arg158. The cavity near the phosphate initially widens as the
phosphate is also hydrated. Accompanying this is a conforma-
tional change in the S6-S7 loop and an 11 Å movement of
Arg213 by 10 ns as it moves to make a salt bridge with the
phosphate (Fig. 11B, iv). It appears that this takes place because
the space between the phosphate and Arg213 is separated by
FIGURE 8. Thermal stability of p53 serine 215/269 substitution mutants.
A, thermal melting profile of p53 mutants. Unfolding of p53 mutants was
monitored between 15 and 55 °C using SYPRO Orange fluorescent dye, and
melt curves were generated by plotting SYPRO Orange fluorescence as a
function of temperature. B, phase transitions in the thermal melting profile.
The gradient of p53 unfolding was plotted as a function of temperature to
obtain the midpoint temperature transition (Tm) for each variant. Midpoint
transition temperatures for each mutant are indicated. RFU, relative fluores-
cent units.
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only a few water molecules when the phosphate is temporarily
hydrated. This gives the space between the negatively charged
phosphate and the positively charged Arg213 a low dielectric
character, which results in the Arg213 moving toward the phos-
phate. The resulting salt bridge extends an existing network
that involves Arg213-Ser(P)215-Arg158-Asp258-Arg156, and this
remains quite robust. During the transition of Arg213, a hydro-
phobic interaction between Pro98, Met160, Ile162, and Thr211 that
appears toweakly tether theN-terminal loop to the surface of p53
isbrokenby themigratingArg213.This triggers thepeelingawayof
the N-terminal loop and also results in destabilization of regions
that are at the dimerization and DNA binding interface.
In the S215A/S269A double mutant, the lack of hydrogen
bonds between the side chain at 215 or 269 with Leu206 and
FIGURE 9. The effect of consensus DNA on the stability of p53 core domains S215A and S269A mutants. Unfolding of p53 wild type (A), p53S215A (B),
p53S269A (C), andp53S215/269A (D) wasmeasuredbetween15 and60 °C in thepresenceof increasing concentrations of consensusDNA. Themidpoint unfolding
transition temperatures are indicated in E. Thermal analyseswereperformed in triplicate; however, a single trace representative of eachmutant is shown. F, the
binding activity of p53 wild type, p53S215A, p53S269A, or p53S215A/S269A (300 or 600 ng) was determined in reactions containing the p21 promoter sequence.
DNA-p53 complexes were resolved using a native polyacrylamide gel, dried, and detected by storage phosphor screen. Bound and free probe are highlighted
by arrows.
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Gln100, respectively, leads to local destabilization, which prop-
agates in such amanner that the loop containing Leu206 loses its
interactions with the Pro98 region, undergoes a conformational
change, and is accompanied by the moving away of the N-ter-
minal loop (Fig. 11B, iii).
DISCUSSION
Unfolding of the p53 Core DNA-binding Domain by Phosphor-
ylation at Ser269—The transcriptional activity of p53, its sta-
bility, and its turnover are regulated by multiple post-transla-
tional modifications, including acetylation, ubiquitination-like
modifications, and phosphorylation (57). Ubiquitination tar-
gets p53 for degradation by the proteasome, p53 acetylation
facilitates recruitment of co-activators, and phosphorylation
facilitates changes in its specific activity as a transcription factor
by altering protein-protein interactions (58). The binding of
MDM2 to the N-terminal LXXLL motif of p53 induces confor-
mational changeswithinMDM2 that enhance its binding to the
ubiquitination peptide signal (SXXLXGXXXF) within the flex-
ible linker in the DNA-binding domain of p53 (26, 59). Phos-
phorylation of p53 also requires allosteric interactions between
kinases that bind within the flexible linker in the DNA-binding
domain or at sites in the tetramerization domain. Thus, this
central flexible motif (Fig. 2) (24) forms a common docking site
that allostericallymodulates the activity of several enzymes that
regulate p53 function. This underscores the importance of the
flexible linker in the DNA-binding domain of p53 in coordinat-
ing incoming stress signals and p53 activity.
FIGURE 10. The effects of Ser215 and Ser269 mutation on p53 function;
phosphomimetic substitution or double alanine substitution of p53 at
Ser215 or Ser269 inactivates p53. The effect of serine 215 and serine 269
mutation on expression of the downstream target genes of p53 was exam-
ined by immunoblotting lysates derived from H1299 cells transfected with
pcDNA vector containing p53 S215A, S215D, S269A, S269D, S215A/S269A,
S215A/S269D, S215D/S269A, or S215D/S269D. Lysates were blotted for reac-
tivity to DO-1 (A), MDM2 (B) (2A10), and p21 (C).
FIGURE 11.Model summarizing the effect of phosphorylation at the conformationally flexiblemotif on p53 activity. A, i, diagramof the structure of thewild
typep53coredomain (ProteinDataBankentry2FEJ)highlightingtheSer269 regionand itsproximity to the flexiblemotif (residues100–103). ii, theepitope is inorange
color,whereasthe loopandhelix that interactwiththeDNAareshowninyellowandbrown, respectively. ii–iv,moleculardynamicsmodelingsnapshotsofp53mutants
to give rise tomechanisms of p53 unfolding over time. Shown are phospho-Ser269 effects on p53. ii, wild type p53 highlighting interactions of Ser269 with Thr102 and
Gln100; iii, thephospho-Ser269 intermediate; iv,phospho-Ser269.Becausenostabilizingcationicsidechainsexistnearthephosphate, thenegativelychargedphosphate
is energetically more stable when solvated by water. This is accompanied by the movement away of the N-terminal loop and destabilization of the DNA binding
regionsplus thedimerization interface.B,molecular dynamicsmodeling snapshotsofp53mutants togive rise tomechanismsofp53unfoldingover time. Shownare
Asp269 or Ala269 effects on p53. i, S269A final molecular dynamics snapshot; ii, S269D final molecular dynamics snapshot; iii, superposition of wild type and double
alanine finalmoleculardynamics snapshot; iv,moleculardynamicsmodelingsnapshotsofp53mutants togive rise tomechanismsofp53unfoldingover time.Shown
are phospho-Ser215 effects onp53 and thephospho-Ser215 intermediate showing the network of interactions. Phosphorylation at Ser215 leads to the formation of an
extended network that involves Arg213-Ser(P)215-Arg158-Asp258-Arg156.
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In the accompanying study (24), the p53 multiprotein dock-
ing domain containing the MDM2 ubiquitination signal is
shown to harbor a phosphorylation site at Ser269 (Fig. 11). The
inactivity of p53S269D in cells suggests that this phosphorylation
would be inactivating.
In this paper, we have characterized biochemically this
phosphomimetic p53 mutant to determine how phosphory-
lation could inactive p53. The phosphomimetic mutant
destabilized the p53 core DNA-binding domain and reduced
sequence-specific DNA binding, thus explaining its reduced
transactivation potential. Molecular dynamics simulations
also suggest that the introduction of negatively charged
phosphate groups at either Ser215 or Ser269 requires either
solvent water or positive charges to stabilize it. There are no
positively charged residues near Ser269, so solvent waters
preferentially hydrate this site, leading to the N-terminal
loop in its vicinity being pushed away, accompanied by the
exposure of the second MDM2 binding site in the S10
-strand. In contrast, two positively charged residues,
Arg158 and Arg213 are coordinated by Ser(P)215; the latter
results from a large conformational change, which also dis-
rupts the interaction of the N-terminal loop with the p53
surface. In the case of S269D, the planar anionic environ-
ment of the carboxyl group leads to the formation of a novel
salt bridge with Lys101 that is accompanied by local struc-
tural rearrangements. Both events lead eventually to desta-
bilization of the p53 core DNA-binding domain (Fig. 11).
In light of our current studies, the interaction between the
S10--strand (containing the MDM2 binding site and the
Ser269 phosphorylation site) and the motif (residues 100–103)
preceding the S1--strand requires further evaluation. This
flexiblemotif between positions 100 and 102 is not as well stud-
ied, given that a significant number of p53 DNA-binding
domain analyses begin with residue 102/103, which is just prior
to the start of the structured S1--strand. However, there are
previous reports suggesting an important role for this motif.
First, although residues 100–102 donot generally represent hot
spots in a large range of human cancers, there is a report indi-
cating that it is a hot spot for mutations in adrenal cancers (60).
These mutations in this motif can include Q100R, K101N, and
T102I, any of which could destabilize the interaction of this
motif with the S10--strand (Fig. 11A). Additionally, NMR
studies have shown that conformational changes can be
detected in this motif of p53 (residues 101–103) after the inter-
action with peptides from the central domain of MDM2 (61).
This might lead to “unfolding” of p53 as a prerequisite for sub-
strate ubiquitination catalyzed by MDM2. A recent structural
analysis of p53 tetramers also suggested an important role for
Gln100 and Lys101 at the dimer interface (62), whichwe have not
evaluated in our current study. The Glu224 of one monomer
forms a pair of hydrogen bonds with the main-chain amide of
Gln100 and Lys101 of an adjacent monomer. Also, Lys100 from
one monomer donates a hydrogen bond to the carbonyl of
Val225 of an adjacent monomer. These clinical and biophysical
data suggest an important functional interaction between the
S10--strand and the flexible motif (residues 100–103) and
suggest a mechanism underlying the ability of Ser269 phosphor-
ylation to destabilize p53 conformation.
The overproduction of the kinases and phosphatases that
target this serine 269 site on p53 has implications for how cells
might produce two distinct forms of wild type p53 in response
to DNA damage; (i) one form of wild type p53 is transcription-
ally active coordinated in part by phosphorylation at sites
including Ser20 and Ser15, and (ii) the other form of wild type
p53 with a radiation-induced phosphorylation at Ser269 (24) is
inactive and would have function independent of the classic
wild type p53 transcription program. Because mutant forms of
p53 have distinct subcellular localizations and functions (63),
the phospho-Ser269 form of wild type p53 protein might have
similar physiological functions. The identification of the kinase
and phosphatases that regulate this equilibrium in wild type
p53, between hypophosphorylation and hyperphosphorylation
at Ser269, has implications for wild type p53 inactivation in
human cancers. The kinases and/or kinase-signaling pathways
that target the Ser269 in vivo remain to be defined.
The Role of the Two Conformationally Flexible Phosphoryla-
tion Sites in Regulating the Folding of the p53 DNA-binding
Domain—The core DNA binding drives specific DNA binding
and forms a highly structured domain (52). The  sandwich
loop-sheet-helix motif in p53 is stabilized by many hydropho-
bic and electrostatic interactions; however, the thermodynamic
stability of this region is low, andmissensemutations can easily
destabilize the core domain (52). There are three major classes
of p53mutants: (i) DNA contact mutations (R273H) remaining
in a folded conformation, (ii) weakly destabilized and partially
unfolded mutants (G245S) that are unable to bind DNA, and
(iii) mutants (R175H) that are highly destabilized and globally
unfolded and aggregate at physiological temperatures (50).
Phosphorylation of p53 (or S269D phosphomimetic mutation)
should lead to global unfolding of the core domain and create a
mutant with characteristics like p53R175H. Not all p53 muta-
tions inactivate transcriptional activity; some mutants show a
gain of function on a subset of genes thatmay promote tumoro-
genic growth (reviewed in Refs. 64 and 65). Many gain-of-func-
tion mutants show altered selectively for subsets of p53 target
genes. For example, p53R213Q is able to potently induce Mdm2
yet is unable to induce expression of apoptosis-inducing genes
PIG3 and PIG11 (66). Other mutant forms of p53 display dif-
ferential gene expression through binding to DNA at sites lack-
ing p53-responsive elements or as a result of altered interaction
with transcription factors such as Ets1 and Sp1 and act in a
manner opposite that of wild type p53 (67). The increase in
specific activity and thermoinstability of p53S269A appears dif-
ferent mechanistically from the incremental increase in p53
thermostability and activity previously induced via mutation of
up to four amino acids in the DNA-binding domain (48, 68). By
contrast to the inactive S269D mutant p53, p53S269A forms a
control for specificity because it was (i) more active than the
wild type p53 at inducing endogenous p21 andMdm2, (ii) more
flexible as defined by red shift in tryptophan fluorescence, and
(iii) more thermally unstable as defined by thermal shift assays.
Simulations revealed that although the S269A mutation looses
the hydrogen bonding with Gln100 and Thr102, providing a
rationale for reductions in thermostability (Fig. 7), Ala269 does
not form a destabilizing bridge with this chain (Fig. 11) because
p53 activity in cells can be partially improved upon by the serine
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to alanine substitution at codon 269 and produce a structurally
modified form of p53 with a reduced thermostability but with
an elevated specific activity in cells. The latter finding suggests
that increasing the flexibility and thermoinstability of p53 can
perhaps increase its ability to adopt different conformations
with transcriptional components in cells.
A phosphorylation sitewas also previously reported at Ser215,
but a mechanism to account for p53 inactivity was not demon-
strated (22). This site is notable in that it contains the confor-
mationally flexible PAb240 monoclonal antibody epitope that
can be used to define p53 mutant unfolding in human cancers
(56). Similar to the p53S269A protein, p53S215A is as active as
wild type p53, but the phosphomimetic mutant p53S215D is
thermally unstable (Figs. 7–9). These data suggest that both
Ser215 and Ser269 phosphorylation convert wild type p53 to the
mutant misfolded conformation. Surprisingly, the double Ala
mutant protein, p53S215A/S269A, is completely inactive in cells
and is significantlymore thermally unstable than the individual,
active alanine mutants (Figs. 7–9). Molecular dynamics simu-
lations also suggest that the double alanine mutant is unable to
maintain the intradomain interactions required to maintain
p53 conformation (Fig. 11B, iv) and suggest an important dual
role for Ser215 and Ser269 in stabilizing WT p53.
A previous report also highlighted a novel role of phosphor-
ylation in driving destabilization of a target protein. The splic-
ing regulatory protein KSRP has a phosphoacceptor site at
Ser193 whose phosphorylation leads to unfolding of the protein
as defined by NMR (70). This unfolding allows access of the
phosphomotif to 14-3-3 that in cells regulates compartmental-
ization of the protein. Similar to our studies on p53, biophysical
studies demonstrated that an alanine mutation at codon 193
has little effect on the stability of the protein, but asparatemuta-
tion increases significantly the thermoinstability of KSRP. The
hydration of phosphate observed here from the molecular
dynamics simulations (Fig. 11) may be a feature that is more
ubiquitous. A recent report examining the binding of the POLO
box binding domain to phosphopeptides (71) using molecular
dynamics simulations found similarly that negatively charged
phosphate groups can contribute significantly to binding by
stabilizing several waters of hydration; indeed, the authors
found that these very same water molecules in the absence of
phosphorylation, are energetically unfavorable. Further work
on other systems will clearly reveal more information on how
water molecules of hydration modulate interactions in biology.
In summary, biophysical studies have shown that the p53
core domain is thermodynamically unstable and that phosphor-
ylation in the DNA-binding domain could inactivate p53 by
enhancing intrinsic thermoinstability. This reversible ther-
moinstability of p53 is the feature by which there is promise in
reactivating mutant, inactive p53 (72). p53 stability can be
enhanced by interacting proteins, and evidence for this
dynamic regulation through docking interactions has emerged
in recent years as an additional layer of regulation for the com-
plex signaling network (69, 73). In this study, we show that
phosphomimetic mutation within the MDM2 ubiquitination
signal also destabilizes p53 structure and function. This pro-
vides a model to describe how phosphorylation at Ser269 would
inactivate p53 in cells. Because the Ser215 phosphorylation site
in another conformationally flexible loop also has a phosphor-
ylation site, these data indicate that the two surface loop serine
residues can function not only as phosphorylation sites but that
they together are required to maintain the thermostability of
p53. This also identifies an intriguing paradigm in p53 protein
evolution; it has two kinase phosphoacceptor sites that regulate
the thermostability of p53 by virtue of controlling the equilib-
rium between folded and unfolded states.
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